Evaluation of the oncolytic potential of R 2 B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620)

Virotherapy is emerging as an alternative treatment of cancer. Among the candidate oncolytic viruses (OVs), Newcastle disease virus (NDV) has emerged as a promising non-engineered OV. In the present communication, we explored the oncolytic potential of R B Mukteshwar strain of NDV using SW-620 colon...

Full description

Saved in:
Bibliographic Details
Published inArchives of virology Vol. 162; no. 9; p. 2705
Main Authors Sharma, Kishan K, Kalyani, Irsadullakhan H, Mohapatra, Jogeswar, Patel, Satish D, Patel, Dharmesh R, Vihol, Priti D, Chatterjee, Abhijit, Patel, Dinesh R, Vyas, Bhavesh
Format Journal Article
LanguageEnglish
Published Austria 01.09.2017
Online AccessGet full text

Cover

Loading…
More Information
Summary:Virotherapy is emerging as an alternative treatment of cancer. Among the candidate oncolytic viruses (OVs), Newcastle disease virus (NDV) has emerged as a promising non-engineered OV. In the present communication, we explored the oncolytic potential of R B Mukteshwar strain of NDV using SW-620 colon cancer cells. SW-620 cells were xenografted in nude mice and after evaluation of the safety profile, 1 x 10 plaque forming units (PFU) of NDV were inoculated as virotherapeutic agent via the intratumoral (I/T) and intravenous (I/V) route. Tumor growth inhibition was compared with their respective control groups by gross volume and histopathological evaluation. Antibody titer and virus survival were measured by hemagglutination inhibition (HI)/serum neutralization test (SNT) and real-time PCR, respectively. During the safety trial, the test strain did not produce any abnormal symptoms nor weight loss in BALB/c mice. Significant tumor lytic activity was evident when viruses were injected via the I/T route. There was a 43 and 57% tumor growth inhibition on absolute and relative tumor volume basis, respectively, compared with mock control. On the same basis, the I/V route treatment resulted in 40 and 16% of inhibition, respectively. Histopathological examination revealed that the virus caused apoptosis, followed by necrosis, but immune cell infiltration was not remarkable. The virus survived in 2/2 mice until day 10 and in 3/6 mice by day 19, with both routes of administration. Anti-NDV antibodies were generated at moderate level and the titer reached a maximum of 1:32 and 1:64 via the I/T and I/V routes, respectively. In conclusion, the test NDV strain was found to be safe and showed oncolytic activity against the SW-620 cell line in mice.
ISSN:1432-8798